

**DOCKET NO.: ISIS-5207**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In Re Application of:**

**Brenda F. Baker, et al.**

**Confirmation No.: 5280**

**Application No.: 10/701,236**

**Group Art Unit: 1635**

**Filing Date: November 4, 2003**

**Examiner: Tracy Ann Vivlemore**

**For: SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND  
COMPOSITIONS FOR USE IN GENE MODULATION**

ELECTRONICALLY FILED:

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☒ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

☒ Copies of reference numbers **351-944** listed on the attached Form PTO-1449 are enclosed herewith.

☒ Copies of reference numbers **1-350** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(ii).

**The enclosed 1449 form includes references cited in related applications. For the Examiner's convenience, also being submitted herewith is a table listing related applications and references cited in official actions issued in the related applications that served as the basis for rejections under 35 U.S.C. § 102 or § 103.**

☒ The relevance of those listed references which are not in the English language is as follows:

English language abstracts have been provided for those listed references which are not in the English language.

**DOCKET NO.: ISIS-5207**

**- 3 -**

**PATENT**

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Date: August 26, 2009

/Jane E. Inglese/

Jane E. Inglese  
Registration No. 48,444

WOODCOCK WASHBURN LLP  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439